image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 116.11
3.73 %
$ 6.52 B
Market Cap
-252.41
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one RGEN stock under the worst case scenario is HIDDEN Compared to the current market price of 116 USD, Repligen Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one RGEN stock under the base case scenario is HIDDEN Compared to the current market price of 116 USD, Repligen Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one RGEN stock under the best case scenario is HIDDEN Compared to the current market price of 116 USD, Repligen Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart RGEN

image
$180.0$180.0$170.0$170.0$160.0$160.0$150.0$150.0$140.0$140.0$130.0$130.0$120.0$120.0$110.0$110.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
634 M REVENUE
0.33%
-35.1 M OPERATING INCOME
-73.61%
-25.5 M NET INCOME
-61.37%
175 M OPERATING CASH FLOW
53.97%
-86.4 M INVESTING CASH FLOW
29.93%
-82.9 M FINANCING CASH FLOW
-33.30%
168 M REVENUE
8.18%
-36.5 M OPERATING INCOME
-366.05%
-33.9 M NET INCOME
-5086.68%
39.2 M OPERATING CASH FLOW
-20.57%
-64.8 M INVESTING CASH FLOW
-1005.34%
1.45 M FINANCING CASH FLOW
102.08%
Balance Sheet Repligen Corporation
image
Current Assets 784 M
Cash & Short-Term Investments 757 M
Receivables 0
Other Current Assets 26.6 M
Non-Current Assets 1.76 B
Long-Term Investments 0
PP&E 333 M
Other Non-Current Assets 1.43 B
29.73 %13.08 %56.15 %Total Assets$2.5b
Current Liabilities 127 M
Accounts Payable 0
Short-Term Debt 15.1 M
Other Current Liabilities 112 M
Non-Current Liabilities 730 M
Long-Term Debt 671 M
Other Non-Current Liabilities 59 M
13.03 %78.32 %6.89 %Total Liabilities$856.9m
EFFICIENCY
Earnings Waterfall Repligen Corporation
image
Revenue 634 M
Cost Of Revenue 360 M
Gross Profit 275 M
Operating Expenses 310 M
Operating Income -35.1 M
Other Expenses -9.6 M
Net Income -25.5 M
700m700m600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)634m(360m)275m(310m)(35m)10m(26m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
43.29% GROSS MARGIN
43.29%
-5.53% OPERATING MARGIN
-5.53%
-4.02% NET MARGIN
-4.02%
-1.29% ROE
-1.29%
-0.90% ROA
-0.90%
-1.36% ROIC
-1.36%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Repligen Corporation
image
160m160m140m140m120m120m100m100m80m80m60m60m40m40m20m20m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -25.5 M
Depreciation & Amortization 86.6 M
Capital Expenditures -32.9 M
Stock-Based Compensation 48.1 M
Change in Working Capital 0
Others 66.3 M
Free Cash Flow 142 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Repligen Corporation
image
Wall Street analysts predict an average 1-year price target for RGEN of $193 , with forecasts ranging from a low of $155 to a high of $220 .
RGEN Lowest Price Target Wall Street Target
155 USD 33.49%
RGEN Average Price Target Wall Street Target
193 USD 66.57%
RGEN Highest Price Target Wall Street Target
220 USD 89.48%
Price
Max Price Target
Min Price Target
Average Price Target
220220200200180180160160140140120120100100May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Repligen Corporation
image
Sold
0-3 MONTHS
4.08 M USD 1
3-6 MONTHS
3.39 M USD 1
6-9 MONTHS
5.1 M USD 2
9-12 MONTHS
3.38 M USD 1
Bought
37.7 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
600 K USD 3
9-12 MONTHS
7. News
Repligen: Ongoing Bioprocessing Market Recovery I reiterate a 'buy' rating for Repligen with a one-year price target of $175 per share, driven by strong bioprocessing market recovery. Repligen reported 3% organic revenue growth and 13% growth in non-COVID business, with record-high order intakes since Q2 FY22. The acquisition of 908 Devices' bioprocessing analytics portfolio enhances Repligen's process analytical technology, adding significant value to its offerings. seekingalpha.com - 1 month ago
908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth On Tuesday, Repligen Corporation RGEN purchased 908 Devices Inc.'s MASS desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. benzinga.com - 1 month ago
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices Portfolio includes PAT devices for real-time process monitoring, control and analysis Portfolio includes PAT devices for real-time process monitoring, control and analysis globenewswire.com - 1 month ago
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices WALTHAM, Mass., & BOSTON--(BUSINESS WIRE)--Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (Nasdaq: MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices' desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on the growth of its newly expanded handheld device. businesswire.com - 1 month ago
Repligen's Q4 Earnings Beat Estimates, Revenues In Line RGEN reports decent fourth-quarter results and issues guidance for 2025. zacks.com - 1 month ago
Repligen Corporation (RGEN) Q4 2024 Earnings Call Transcript Repligen Corporation (NASDAQ:RGEN ) Q4 2024 Earnings Call Transcript February 20, 2025 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Olivier Loeillot - President and Chief Executive Officer Jason Garland - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Rachel Vatnsdal - J.P. Morgan Puneet Souda - Leerink Partners Matt Larew - William Blair & Company Jacob Johnson - Stephens Inc. Conor McNamara - RBC Capital Markets Matt Hewitt - Craig Hallum Subbu Nambi - Guggenheim Securities Justin Bowers - Deutsche Bank Paul Knight - KeyBanc Capital Doug Schenkel - Wolfe Research Operator Good day, ladies and gentlemen. seekingalpha.com - 1 month ago
Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook Repligen Corp RGEN released its fourth-quarter adjusted EPS of 44 cents on Tuesday, down from 48 cents a year ago but beating the consensus of 41 cents. benzinga.com - 1 month ago
Repligen's Q4 Slightly Tops Expectations Repligen (RGEN 7.92%), a bioprocessing technology company, announced its earnings for the fourth quarter on Feb. 20. Its adjusted earnings per share (EPS) of $0.44 exceeded analysts' consensus estimate of $0.41, but fell year over year. fool.com - 1 month ago
Repligen (RGEN) Beats Q4 Earnings Estimates Repligen (RGEN) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.33 per share a year ago. zacks.com - 1 month ago
Repligen to Report Fourth Quarter and Full Year 2024 Financial Results Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET globenewswire.com - 2 months ago
HRMY vs. RGEN: Which Stock Is the Better Value Option? Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN). But which of these two stocks presents investors with the better value opportunity right now? zacks.com - 2 months ago
Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains? Repligen (RGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. zacks.com - 2 months ago
8. Profile Summary

Repligen Corporation RGEN

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 6.52 B
Dividend Yield 0.00%
Description Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Contact Building 1, Waltham, MA, 02453 https://www.repligen.com
IPO Date April 29, 1986
Employees 1778
Officers Ms. Sondra S. Newman Global Head of Investor Relations Mr. James R. Bylund Chief Operating Officer Mr. Olivier Loeillot President, Chief Executive Officer & Director Mr. Neil Whitfield Vice President & Global Head of Sales Ms. Kimberly A. Cornwell Global Head of Legal Mr. Anthony J. Hunt Executive Chair Mr. Keith Lee Robinson Chief Information Officer Mr. Jason K. Garland Chief Financial Officer & Chief Compliance Officer Mr. Ralf Kuriyel Senior Vice President of Research & Development Ms. Teresa Ferragamo Senior Director of Marketing